

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Elfi Biedermann, et al.	<b>Examiner:</b>	Benjamin J. Packard
<b>Serial No:</b>	10/509,362	<b>Art Unit:</b>	4173
<b>Filed:</b>	April 15, 2005	<b>Docket:</b>	21371
<b>For:</b>	USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS	<b>Dated:</b>	April 25, 2008

**Confirmation No.:** 3950

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR RECONSIDERATION OF RESTRICTION REQUIREMENT AND  
SPECIES ELECTION UNDER 37 C.F.R. §1.475(b)**

Sir:


In response to the Official Action dated October 26, 2007, applicants provisionally elect, with traverse, pursuant to the imposed restriction requirement, Group I, drawn to a method of inhibiting or reducing angiogenesis in a mammal, which is encompassed by Claims 15-26 and 29-30, and further provisionally elects, with traverse, N-[4-(1-benzoyl-piperidin-4-yl)-butyl]-3-(pyridin-3-yl)-acrylamide as listed in Claim 22 and further provisionally elects, with traverse, inflammatory disorder as a specific disease of Claim 24 for prosecution on the merits in this application.

---

**CERTIFICATE OF ELECTRONIC FILING**

I hereby certify that this correspondence is being deposited with the United States Patent & Trademark Office via Electronic Filing through the United States Patent and Trademark Office e-business website.

Dated: April 25, 2008

  
\_\_\_\_\_  
Peter I. Bernstein